News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QIAGEN (QGENF) Expands Strategic Alliance With Protedyne Targeting Ultra High-Throughput Markets Of Molecular Diagnostics And Pharmaceutical Research



10/19/2005 5:12:36 PM

VENLO, The Netherlands and WINDSOR, Connecticut, February 1 /PRNewswire-FirstCall/ -- QIAGEN N.V. (NASDAQ: QGENF; Frankfurt, Prime Standard: QIA), one of the world's leading providers of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins, and Protedyne Corporation, a premier supplier of ultra-high throughput industrial robotics for research, drug discovery, and testing laboratories today announced that they have expanded their strategic alliance to jointly market and cross-promote the use of Protedyne's BioCube System in conjunction with QIAGEN's QIAamp nucleic acid purification products as an integrated fully automated ultra high-throughput sample preparation system for high-throughput research and molecular diagnostics markets.

In addition, QIAGEN will invest approximately US$ 2.0 million in Protedyne's current series D financing. QIAGEN has been granted exclusive access to Protedyne's high-throughput automation platform technologies for filter-based nucleic acid sample preparation. This strategic alliance is the result of a successful collaboration announced in June 2004. The first commercial system will be available during Q2 of 2005. Both parties expect to expand their collaboration to add and validate further customer applications.

Protedyne's BioCube system addresses the needs of customers requiring ultra-high-throughput and fully integrated preanalytical and analytical processing in molecular diagnostics and clinical research. For these applications, Protedyne has built a leading position. This expanded alliance addresses ultra-high throughput systems (larger than 600 samples per day) and therefore uniquely complements QIAGEN's leading position in automated solutions extending from low-throughput platforms to high-throughput systems.

QIAGEN's proprietary nucleic acid sample preparation and handling technologies provide standardized procedures in all preanalytical sample preparation steps, from sample collection to separation, purification and handling of DNA and RNA in clinical research and molecular diagnostics fields and complements Protedyne Corporation's industrial laboratory automation solutions for ultra high-throughput sample processing in progressive biotechnology, diagnostics, and pharmaceutical companies.

"We are pleased to extend this important strategic move with Protedyne," said Noel Doheny, QIAGEN's Vice President Molecular Diagnostics. "Protedyne's industrial BioCube(TM) System enables us to enter the next step of standardization of ultra-high throughput applications with QIAGEN's preanalytical sample preparation technologies. Integrated solutions as a result of this alliance will provide further value to our ultra high-throughput customers in molecular diagnostic markets and clinical research environments who are demanding the utmost in reliability and efficiency. As partners based on the natural compatibility of our platforms in sample preparation and complete automation QIAGEN and Protedyne will further develop integrated customer solutions to meet the needs and the demands coming from this exciting, emerging field. "

"We are very proud that QIAGEN has expanded its strategic alliance with Protedyne and has also demonstrated its commitment though a financial investment," said Don Schoeny, president of Protedyne. "The fact that a company of QIAGEN's caliber believes so strongly in our automation speaks volumes for the future of Protedyne."

About QIAGEN:

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,400 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com/.

About Protedyne:

Protedyne's unique approach combines scientific and automation expertise with industrial-quality automation and sophisticated data management. The foundation of the company is the BioCube(TM) System, which brings advanced industrial automation capabilities into life science and diagnostic laboratories in a fast, flexible, and reliable package. Protedyne is headquartered in Windsor, Connecticut. For more information, call +1-860-683-1860 in North America or visit Protedyne on the web at http://www.protedyne.com/.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

Qiagen N.V.

CONTACT: Peer M. Schatz, Chief Executive Officer, QIAGEN N.V., Tel+49-2103-2911-702, e-mail: peer.schatz@QIAGEN.com or Dr.Solveigh Mahler, Manager Investor Relations, QIAGEN GmbH, Tel+49-2103-2911-710, e-mail: solveigh.maehler@QIAGEN.com or NoelDoheny, Vice President Solutions for Molecular Diagnostics,QIAGEN GmbH, Tel +49-2103-2911-238, e-mail:noel.doheny@QIAGEN.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES